Zacks Small-Cap Research

August 18, 2015
Grant Zeng, CFA
312-265-9466
gzeng@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Pressure Biosciences (PBIO-OTC)

PBIO: Another strong quarter for 2Q15, expecting significant revenue growth in 2015 and beyond; valuation very attractive---Buy

Current Recommendation	**Buy**
Prior Recommendation	Neutral
Date of Last Change	11/15/2012
Current Price (08/17/15)	$0.26
Twelve- Month Target Price	**$2.50**

OUTLOOK

PBIO is a research products and services provider for the life science industry. We are impressed with and optimistic about the Company's novel, enabling platform technology PCT which has competitive advantages over existing technologies in the sample preparation market. PCT is increasingly gaining recognition by research labs.

PBIO just reported strong financials for 2Q15, and we expect to see significant revenue growth in 2015 and beyond.

We continue to be bullish on PBIO shares.

SUMMARY DATA

52-Week High	**$0.48**
52-Week Low	**$0.19**
One-Year Return (%)	**-37.57**
Beta	**1.31**
Average Daily Volume (sh)	**59,635**
Shares Outstanding (mil)	**20**
Market Capitalization ($mil)	**$5**
Short Interest Ratio (days)	**3.01**
Institutional Ownership (%)	**N/A**
Insider Ownership (%)	**N/A**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**37.0**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2011 Estimate	**N/A**
P/E using 2012 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**High,**
Type of Stock	**Small-Value**
Industry	**Med Instruments**
Zacks Rank in Industry	**N/A**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	0.40 A	0.31 A	0.37 A	0.29 A	1.37 A
2015	0.44 A	0.41 A	0.53 E	0.63 E	2.01 E
2016					5.25 E
2017					10.25 E

Earnings per Share
(EPS is operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	-$0.19 A	-$0.05 A	-$0.07 A	-$0.09 A	-$0.39 A
2015	-$0.11 A	-$0.07 A	-$0.04 E	-$0.04 E	-$0.26 E
2016					-$0.10 E
2017					$0.02 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

PBIO Reports Strong Financials For 2Q15

On Aug 17, 2015, Pressure BioSciences (PBIO) announced financial results for the fiscal second quarter ended June 30, 2015.

Products and services revenue for 2Q15 was $0.33 million, compared to $0.31 million for the same period in 2014, an increase of 8.5%. Among the products and services revenue for 2Q15, sales of consumables were $56,513, compared to $48,417 for the same period in 2014, an increase of 16.7%.

Grant revenue for 2Q15 was $79,529, compared to no grant revenue for the comparable period in 2014.

Total revenue for the 2015 second quarter was $0.41 million, compared to $0.31 million for the same period in 2014, a 34.4% increase. This increase was due to increases in both product and services and grant revenue in the second quarter of 2015.

R&D expenses for 2Q15 were $0.3 million, compared to $0.3 million for 2Q14.

SG&A expenses for 2Q15 were $1.0 million, compared to $0.8 million for 2Q14.

Operating loss for the 2015 second quarter was $1.1 million, compared to $0.8 million for the same period in 2014.

Net loss for 2Q15 was $1.4 million ($0.07 per share), compared to net loss of $0.7 million ($0.05 per share) for 2Q14.

We are pleased to see that PBIO had another strong quarter. Total revenue increased 34.4% year over year. Even without grant revenue, products and services revenue also increased 8.5%.

We are especially impressed by the strong sales of consumables in fiscal 2Q15, which increased 16.7%. This is important for the long term revenue growth. Consumables are recurring revenue, which should increase when more and more instruments are installed. This revenue may account for a large portion of total revenue in the future.

PBIO expects even stronger revenue growth in the second half of 2015. Based on shipments-to-date, purchase orders received, and serious indications to purchase, the company believe that total revenue will exceed half a million dollars in 3Q15 supported by continued growth in products and services revenue.

Balance Sheet Boosted by Two New Financings

In addition to strong financial results reported for the 2Q15, PBIO also boosted its balance sheet by recent two new financings.

As of June 30, 2015, PBIO held $38,175 in cash.
On Aug 11, 2015, PBIO sold 1,000,000 shares of PBIO common stock to a European institutional investor. The shares of PBIO restricted stock were purchased at an approximate 78% premium to market ($0.46/share) by an investment company managed by one of the most recognized and respected portfolio and fund managers in Poland. In lieu of cash, PBIO received 601,500 shares in the investment company, which is publicly-traded on the Main Market of the Warsaw Stock Exchange. The investment company shares were valued at approximately $460,000 on the day of the transaction.

PBIO and recently formed a **joint venture** with Quark Ventures (QV) in Poland, called PBIO Europe, which intends to submit several multi-million dollar grant requests to a special, strategic economic-development investment portfolio of EU grant programs aimed at supporting innovative companies willing to develop and manufacture such products in Poland, and to subsequently commercialize them throughout Poland, the rest of the EU, and beyond. With QV's guidance, PBIO has begun the process of preparing at least two grant applications for submission, based on the Company's powerful and unique PCT platform.

In support of their business partner, QV has announced their intention to purchase up to $250,000 of PBIO common stock in the open market over the next six months.

On July 23, 2015, PBIO closed on gross proceeds of $2,180,000 from the initial tranche of a $5 million Private Placement. Of the amount invested, $1,520,000 was received in cash and $660,000 was from the conversion of principal and interest on outstanding promissory notes.

Pursuant to the Subscription Agreement, the Company will issue Senior Secured Convertible Debentures with a fixed conversion price of $0.28 per restricted common share, and Common Stock Purchase Warrants exercisable into a total of 3,892,857 shares of restricted common stock at an exercise price of $0.40 per share.

The Company netted $1,340,000 in cash after taking into account fees related to the Offering and the value of the notes that converted into the Offering.

We welcome these financings as it not only boosts the company’s balance sheet, but further validate the company’s platform PTC technology and commercial potential. Proceeds from these two financings will support expansion of marketing and sales team which will accelerate revenue growth in the coming quarters.

Update on Other Key Successes in 2Q15

In addition to strong financial results and boosted balance sheet, PBIO also achieved a number of other successes during 2Q15 and the six weeks that followed, including:

- PBIO is collaborating with Southern University at New Orleans to develop methods for improving and extending applications of the PCT platform for DNA detection in forensic samples.
- Scientists from Northwestern Univ. used PCT to extract cotinine (metabolite of nicotine) from dried blood spots and theorized that PCT might also improve the extraction of other chemical toxins and carcinogens.
- Three scientific articles were published that show the key advantages of the PCT platform in drug discovery & design, cancer detection, and in the analysis of microbial communities in soil.
- Scientists from the Institute of Molecular Systems Biology in Zurich, Switzerland presented data on an improved method for the proteomic profiling and classification of prostate cancer tissue biopsy samples.
- Promising results were reported by forensic expert Dr. Bruce McCord when PCT was incorporated into a new method for improving the extraction of DNA from rape kits and other forensic samples.
- Chinese and Swiss researchers suggested a PCT-based workflow that could potentially accelerate the discovery of new biomarkers for the early diagnosis and prediction of complications in diabetes.
- PCT was a key workflow component in a study to discover potential biomarkers and underlying pathways in the emergence and progression of COPD-associated lung cancer.

We Expect Significant Revenue Growth in second half of 2015 and beyond

Although quarterly revenue fluctuates, we see the clear growth trend in the past few quarters.

PBIO has set a series of goals for 2015, which include:

- Achieve measureable progress in completing and implementing a sound roadmap toward financial self-sufficiency and future growth and prosperity.
- Increase products and services sales and/or total revenue over same quarter prior year.
- Continue the Barozyme HT48 commercialization plan Phase III (initial sales of high throughput systems) with increasing numbers of systems sold quarter over quarter.
- Secure a strategic marketing and distribution partner for the Barozyme HT48 high throughput system and for the NMR and EPR PCT-based sample preparation systems.
- Make measurable progress on the possible spin-off of selected PCT applications into new, stand-alone businesses designed to generate a revenue stream and favorable visibility for PBIO.
- Implement an expanded marketing campaign for the recently released, patent-pending micro-Pestle consumable.
- Continue to expand its sales and marketing capabilities and reach into new countries, investigators, and fields-of-use.

Based on these efforts and the strong financial performance for 1H15, as well as the two new products launch and continued marketing efforts by management, we continue to believe revenue will grow significantly in 2015 and beyond. Specifically we believe products and services revenue for 2015 will reach $1.7 million, exceeding the $1.5 million mark first time in the company's history. Total revenue for 2015 will reach $2.0 million.

These increases will be driven by sales from both existing and new products (instruments and consumables), from the Company's expanding distribution network, and from the additional sales and marketing personnel the company is committed to hire. We further believe that the PBIO's new high-throughput Barozyme HT48 instrument and PCT-HD consumable will help the company secure a marketing and distribution deal with one or more major strategic partners.

PBIO Announces the Release of PCT-HD, "The Next Generation Protein Preparation System"

On March 12, 2015, PBIO announced the commercial release of the **PCT-HD system**. The Company highlighted PCT-HD at the annual meeting of the US Human Proteomic Organization (US HUPO), being held March 15-18 in Tempe, Arizona.

Key advantages of the PCT-HD System in the application of biomarker discovery were discussed in two separate presentations during the conference.

The PCT-HD System combines two of the Company's unique products: the recently released, patent-pending micro-Pestle consumable with an enhanced Barocycler NEP2320 instrument. This combination enables faster, less cumbersome and higher quality homogenization, extraction, and digestion of proteins.

The introduction of the PCT-HD System to the worldwide proteomics market marks an important milestone for PBIO. In addition to the key advantages of greater speed, easier handling, and increased quality, the PCT-HD System also offers a level of flexibility that will greatly support its adoption and growth across multiple markets, therefore boosting PBIO's top line growth in the coming years.

PBIO Shares are undervalued

We maintain our **Buy** rating on PBIO shares and reiterate our twelve-month price target of $2.50 per share.

PBIO reported 34% increase in total revenue in 2Q15. We expect significant revenue growth in the rest of 2015 and beyond due to three new products launch and continued marketing efforts from management.

In terms of valuation, we think PBIO shares are undervalued based on the Company's fundaments. Currently, the Company trades around $0.26 per share with a market cap of $5.2 million based on 20 million outstanding shares. We believe this deeply undervalues the Company based on the current fundamentals we discussed above. We understand that market discounts the value of the Company because the Company has only limited revenue base and has been losing money since its inception. We also understand that the Company has a relatively weak balance sheet, and further financing will be needed. However, when we look at the Company and the industry in which it operates in detail, we realize that PBIO is a company with huge opportunity and one that can grow its revenue and earnings at a tremendous rate in the next few years.

PBIO operates in the rather large, but underserved research services market. The Company has developed a unique and superior pressure cycling technology (PCT) for the preparation of biological laboratory samples. The Company's PCT platform holds competitive advantages over incumbent technologies in many important aspects related to sample preparation.

Currently, the Company is in the early stage of commercialization of its platform technology. We have realized that sales have not been stellar so far, but this is understandable. Pressure cycling technology is quite new to most customers in the sample preparation market, and the costs for PCT are also higher than those for most existing technologies. Therefore, rollout of the PCT platform will take time. However, once customers become familiar with the new PCT platform, and realize its advantages over existing technologies, uptake of PCT and its consumable products by the industry will increase dramatically in our view.

We are now optimistic about the Company's prospect. With a rapidly growing market worldwide, combined with its unique technology and broad range of product offering, the Company is well positioned to boost its top line and bottom line in the coming years. According to our long term financial model, the Company's products and services revenue will grow at a compound annual growth rate (CAGR) of 75% in the next five fiscal years from 2015 to 2019. PBIO will become profitable in fiscal 2017 with an EPS of $0.02.

We think PBIO is more like a development stage biotech company. We use a 35x P/E ratio, multiplied by the EPS of $0.18 in 2019, and discount at 25% for 4 years. Then we come up with our price target of $2.50 per share.

Our price target values the company at $50 million in market cap based on 20 million outstanding shares. This valuation is still very conservative in our view. As long as the Company can execute on its growth strategy correctly, we believe this goal is achievable. Patient investors will get rewarded.

PROJECTED INCOME STATEMENT

$ in million except per share data	Q1	Q2	Q3	Q4	12/14A	Q1	Q2	Q3	Q4	12/15E	12/16E	12/17E	12/18E	12/19E
Product/Service Revenue	$0.40	$0.31	$0.37	$0.27	$1.35	$0.36	$0.33	$0.45	$0.55	$1.69	$5.00	$10.00	$15.00	$22.00
YOY Growth	*82.4%*	*56.5%*	*13.6%*	*-11.5%*	*29.0%*	*-11.1%*	*8.5%*	*20.8%*	*106.8%*	*25.4%*	*195.3%*	*100.0%*	*50.0%*	*46.7%*
Grant Revenue	$0.00	$0.00	$0.00	$0.02	$0.02	$0.08	$0.08	$0.08	$0.08	$0.32	$0.25	$0.25	$0.25	$0.25
Total Revenues	**$0.40**	**$0.31**	**$0.37**	**$0.29**	**$1.37**	**$0.44**	**$0.41**	**$0.53**	**$0.63**	**$2.01**	**$5.25**	**$10.25**	**$15.25**	**$22.25**
YOY Growth	*9.0%*	*-14.1%*	*-11.5%*	*-17.9%*	*-8.6%*	*8.9%*	*34.4%*	*42.3%*	*116.8%*	*46.4%*	*160.8%*	*95.2%*	*48.8%*	*45.9%*
CoGS	$0.2	$0.1	$0.1	$0.2	$0.7	$0.2	$0.2	$0.2	$0.2	$0.7	$2.0	$4.0	$6.0	$8.8
Gross Income	**$0.23**	**$0.17**	**$0.22**	**$0.10**	**$0.72**	**$0.25**	**$0.24**	**$0.35**	**$0.41**	**$1.34**	**$3.25**	**$6.25**	**$9.25**	**$13.45**
Gross Margin	*56.1%*	*56.3%*	*60.0%*	*34.2%*	*52.5%*	*56.7%*	*57.6%*	*66.0%*	*65.1%*	*66.4%*	*61.9%*	*61.0%*	*60.7%*	*60.4%*
Gross Margin for PCT revenue	*56.1%*	*56.3%*	*60.0%*	*28.1%*	*51.7%*	*46.9%*	*47.5%*	*60.0%*	*60.0%*	*60.0%*	*60.0%*	*60.0%*	*60.0%*	*60.0%*
R&D	$0.2	$0.3	$0.2	$0.2	$1.0	$0.2	$0.3	$0.3	$0.3	$1.1	$1.4	$1.6	$1.8	$2.0
% R&D	*57.2%*	*82.4%*	*62.3%*	*81.3%*	*69.3%*	*52.7%*	*70.5%*	*52.8%*	*47.6%*	*54.8%*	*26.7%*	*15.6%*	*11.8%*	*9.0%*
SG&A	$0.8	$0.8	$0.8	$0.8	$3.1	$0.9	$1.0	$0.9	$0.9	$3.7	$4.0	$4.2	$4.8	$5.2
% SG&A	*192.5%*	*249.3%*	*211.8%*	*266.6%*	*226.1%*	*202.7%*	*244.6%*	*164.2%*	*142.9%*	*182.4%*	*76.2%*	*41.0%*	*31.5%*	*23.4%*
Other	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
% Other	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*
Operating Income	**($0.8)**	**($0.8)**	**($0.8)**	**($0.9)**	**($3.3)**	**($0.9)**	**($1.1)**	**($0.8)**	**($0.8)**	**($3.4)**	**($2.2)**	**$0.5**	**$2.7**	**$6.3**
Operating Margin	*-193.6%*	*-275.4%*	*-214.1%*	*-313.7%*	*-242.8%*	*-198.8%*	*-257.5%*	*-150.9%*	*-125.4%*	*-170.9%*	*-41.0%*	*4.4%*	*17.4%*	*28.1%*
Other Net	($0.98)	$0.24	($0.16)	($0.38)	($1.27)	($1.17)	($0.32)	$0.00	$0.00	($1.49)	$0.00	$0.00	$0.00	$0.00
Pre-Tax Income	**($1.8)**	**($0.6)**	**($1.0)**	**($1.3)**	**($4.6)**	**($2.0)**	**($1.4)**	**($0.8)**	**($0.8)**	**($4.9)**	**($2.2)**	**$0.5**	**$2.7**	**$6.3**
Pref. stk Div	$1.33	$0.12	$0.04	$0.15	$1.64	$0.02	$0.00	$0.00	$0.00	$0.02	$0.00	$0.00	$0.00	$0.00
Taxes (Benefit)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*
Reported Net Income	**($3.1)**	**($0.7)**	**($1.0)**	**($1.4)**	**($6.3)**	**($2.1)**	**($1.4)**	**($0.8)**	**($0.8)**	**($5.0)**	**($2.2)**	**$0.5**	**$2.7**	**$6.3**
YOY Growth	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Margin	*-763.3%*	*-234.4%*	*-269.1%*	*-496.9%*	*-454.8%*	*-469.0%*	*-335.6%*	*-150.9%*	*-125.4%*	*-246.0%*	*-41.0%*	*4.4%*	*17.4%*	*28.1%*
Shares Out	*12.1*	*13.6*	*15.2*	*16.1*	*14.3*	*18.8*	*19.7*	*18.5*	*20.0*	*19.3*	*22.0*	*25.0*	*30.0*	*35.0*
Reported EPS	**($0.25)**	**($0.05)**	**($0.07)**	**($0.09)**	**($0.44)**	**($0.11)**	**($0.07)**	**($0.04)**	**($0.04)**	**($0.26)**	**($0.10)**	**$0.02**	**$0.09**	**$0.18**
YOY Growth	-	-	-	-	-	-	-	-	-	-	-	-	-	-
One time charge	*$0.73*	*$0.00*	*$0.00*	*$0.00*	*$0.73*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*
Non GAAP Net Income	**($2.4)**	**($0.7)**	**($1.0)**	**($1.4)**	**($5.5)**	**($2.1)**	**($1.4)**	**($0.8)**	**($0.8)**	**($5.0)**	**($2.2)**	**$0.5**	**$2.7**	**$6.3**
Non GAAP EPS	**($0.19)**	**($0.05)**	**($0.07)**	**($0.09)**	**($0.39)**	**($0.11)**	**($0.07)**	**($0.04)**	**($0.04)**	**($0.26)**	**($0.10)**	**$0.02**	**$0.09**	**$0.18**

Source: Company filings and Zacks Investment Research Inc. estimates

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Grant Zeng, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

POLICY DISCLOSURES

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1127 companies whose securities it covers, including securities covered by Zacks SCR:
Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.
Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.
Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 15.7%, Hold/Neutral- 78.3%, Sell/Underperform – 5.8%. Data is as of midnight on the business day immediately prior to this publication.